Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

is open and Janssen plans to enroll 110 patients worldwide.
  • Phase Ib/II dose escalating study of ibrutinib in combination with R-CHOP in patients with newly diagnosed CD20 positive non-Hodgkin's lymphoma. The purpose of this study is to identify a safe and tolerable dose of ibrutinib in combination with R-CHOP, once a safe dose is established the study will expand and report responses of this combination in patients with newly diagnosed DLBCL. This global, multi-center study, conducted by Janssen, is open and Janssen plans to enroll 33 patients.
  • Phase II study of ibrutinib in subjects with relapsed or refractory multiple myeloma (MM): This is a Phase II, multi-center, open-label trial designed trial to assess the safety and efficacy of ibrutinib single agent and in combination with dexamethasone in subjects with relapsed or relapsed MM. This study is conducted by Pharmacyclics and is currently exploring ibrutinib administration at 560 mg in combination with dexamethasone. Two further cohorts are planned to be explored; 840 mg with dexamethasone and 840 mg as a single agent. The Company anticipates an update on this study will be provided by year end 2013.
  • Phase II open-label, multicenter, single-arm study of monotherapy ibrutinib in subjects with relapsed or refractory follicular lymphoma. The primary endpoint of this study is objective response rate. Janssen plans to enroll 110 patients in this study.
  • PCYC has received Orphan Drug and Fast Track designation for ibrutinib treatment of chronic lymphocytic leukemia last year. The FDA has also granted Orphan Drug and Fast Track designation most recently to ibrutinib for the treatment of mantle cell lymphoma.  A US orphan drug designation provides the drug developer with several benefits and incentives related to the orphan drug, including a 7-year period of U.S. marketing exclusivity if the drug is the first of its type approved for the specified indication. Fast tra
    '/>"/>

    SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
    (Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
    (Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
    (Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
    Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
    ... Oct. 24, 2011 Marshall Edwards, Inc. (Nasdaq: ... of novel therapeutics targeting cancer metabolism, announced today that Charles ... Company, has been appointed to its board of directors. The ... to six and the number of independent directors to five. ...
    ... (NYSE symbol: OME), a nutritional ingredient company and the ... fish meal products, today announced that it has retained ... with its omega-3 fish oil and omega-3 concentrate research ... analytical services and biotechnology consulting company that specializes in ...
    ... Oct. 24, 2011 Heart repair.  Bone repair. ...  Cerebral Palsy.  Diabetes.  Alzheimer,s.  Cystic Fibrosis.  Leukemia, Sickle ... metabolic disorders. "These diseases or group ... cured with umbilical cord blood stem cells or ...
    Cached Biology Technology:Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 2Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 3Omega Protein Announces Retention of Lipid Technologies, LLC 2Cord Blood America Provides Insight on Worldwide Research Using Umbilical Cord Blood Stem Cells to Treat Numerous Diseases 2Cord Blood America Provides Insight on Worldwide Research Using Umbilical Cord Blood Stem Cells to Treat Numerous Diseases 3
    (Date:4/22/2014)... club of a mantis shrimp, a team of researchers ... University of Southern California and Purdue University, have developed ... impact resistant and tougher than the standard used in ... this tiny crustacean, the more we realize its structure ... said David Kisailus, a Kavli Fellow of the National ...
    (Date:4/22/2014)... Biology (FASEB) has released updated factsheets for ... National Institutes of Health (NIH) benefits each of the ... to make these factsheets available to help citizens and ... said FASEB President, Margaret K. Offermann, MD, PhD. NIH ... funding, investing $29.2 billion in FY 2013 in medical ...
    (Date:4/22/2014)... begins a trip to Asia to coordinate with ... Pacific, officials at the Office of Naval Research ... Partnership (APTEP) as an example of strong and ... allies in the region. , The APTEP program, ... region, supports the development of alternative energy technologies. ...
    Breaking Biology News(10 mins):Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3Full power: Alternative energy partnerships flourish in Asia 2Full power: Alternative energy partnerships flourish in Asia 3
    ... CREEK, CAMessages from nearly a half-billion years ago, conveyed ... moss, provide clues about the earliest colonization of dry ... Joint Genome Institute (DOE JGI) was among the leaders ... to complete the first genome sequencing project of a ...
    ... published a paper today that is the most comprehensive ... are having on the worlds coral reefs. The ... and Ocean Acidification, co-authored by seventeen marine scientists from ... not survive the drastic increases in global temperatures and ...
    ... The Stowers Institutes Rong Li Lab, in collaboration ... quantitative in vivo measurement of the dynamic protein-protein ... signaling pathway, which is critical to growth and ... paper, Mapping Dynamic Protein Interactions in the MAP ...
    Cached Biology News:DOE JGI Community Sequencing Program delivers first moss genome 2DOE JGI Community Sequencing Program delivers first moss genome 3Immediate action needed to save corals from climate change 2Immediate action needed to save corals from climate change 3Rong Li Lab reports protein interactions of MAP kinase signaling pathway 2
    Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
    This antibody detects ubiquitinated proteins on SDS-PAGE immunoblots. It does not detect free ubiquitin....
    ... The Jouan B4i ventilated and BR4i refrigerated multifunction ... low speed operation at a low sound level ... certified for biocontainment. Their AUTO-LOCK rotor exchange system ... ready for use within seconds. Instant ...
    ... BR4i refrigerated multifunction centrifuges are equally capable of ... low sound level with a large range of ... rotor exchange system without tools ensures that the ... Instant rotor exchange (5 sec.) ...
    Biology Products: